Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC

This study is a Phase II study to evaluate the clinical efficacy and safety of two cycles of induction Toripalimab plus chemotherapy followed by definitive chemoradiotherapy and consolidation Toripalimab therapy for large-volume, unresectable, locally advanced stage II-III non-small cell lung cancer ("large volume" is defined as primary tumor ≥5 cm in greatest dimension or metastatic lymph nodes ≥2 cm in shortest diameter).

Inclusion criteria

• Age 18-75 years; ECOG score 0-1.
• Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
• Unresectable Stage II-III NSCLC (according to AJCC 8th edition) with maximum tumor diameter T ≥ 5 cm in the primary tumor or minimum diameter N ≥ 2 cm in mediastinal metastatic lymph nodes.
• No other previous anti-tumor history, at least 3 months of expected survival.
• No serious medical diseases and dysfunction of major organs, such as blood routine, liver, kidney, heart and lung function.

Exclusion criteria

• Pathologic type was adenocarcinoma with EGFR gene mutation or ALK gene rearrangement.
• Patients with other active malignancies within 5 years or at the same time.
• Active or previously documented autoimmune or inflammatory diseases (including inflammatory bowel disease, diverticulitis [except diverticular disease], systemic lupus erythematosus, Sarcoidosis syndrome, Wegener' s syndrome).
• History of allogeneic organ transplantation.
• History of active primary immunodeficiency.
• Patients with uncontrolled concurrent diseases, including but not limited to persistent or active infection (including tuberculosis, hepatitis B, hepatitis C, human immunodeficiency virus, etc.), symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled arrhythmia, active interstitial lung disease, severe chronic gastrointestinal disease with diarrhea or mental illness.
• Women of child-bearing potential who are pregnant or breastfeeding.
• Allergic to research drug ingredients.
• Ongoing or prior use of immunosuppressive agents within 14 days prior to first dose
• The investigator judged other situations not suitable for inclusion in this study.